%20%EA%B9%80%EC%86%A1%EC%88%98%20HLB%EB%9D%BC%EC%9D%B4%ED%94%84%EC%BC%80%EC%96%B4%20%EB%8C%80%ED%91%9C%EC%9D%B4%EC%82%AC,%20%EC%95%88%EC%B2%A0%EC%9A%B0%20%EA%B0%95%EB%82%A8%EC%84%B8%EB%B8%8C%EB%9E%80%EC%8A%A4%EB%B3%91%EC%9B%90%20%EB%82%B4%EB%B6%84%EB%B9%84%EB%82%B4%EA%B3%BC%20%EA%B5%90%EC%88%98%20%EA%B2%B8%20HLB%EB%9D%BC%EC%9D%B4%ED%94%84%EC%BC%80%EC%96%B4%20%EA%B3%B5%EB%8F%99%20%EB%8C%80%ED%91%9C%EC%9D%B4%EC%82%AC,%20%EC%9D%B4%EA%B7%9C%EC%9B%85%20%EC%A2%85%EA%B7%BC%EB%8B%B9%20%EB%A7%88%EC%BC%80%ED%8C%85%EB%B3%B8%EB%B6%80%EC%9E%A5-800x600.webp)
Leveraging Chong Kun Dang's sales network and diabetes treatment portfolio.
Designed for patients aged two and older; provides 15 days of continuous monitoring with real-time app-based data sharing.
HLB Life Science is joining forces with Chong Kun Dang to expand the domestic distribution of its continuous glucose monitor (CGM), Picoling. Under the agreement, HLB Life Science will supply the product, while Chong Kun Dang will oversee distribution, sales, and marketing to hospitals, clinics, and its online platform, Chong Kun Dang Mall.
HLB Life Science announced on the 13th that it had finalized the sales agreement, with the signing ceremony held at Chong Kun Dang's headquarters in Seodaemun-gu, Seoul, on the 11th.
The two companies plan to integrate HLB Life Science's CGM with Chong Kun Dang's existing sales network and diabetes treatment portfolio, aiming to provide efficient blood glucose management solutions to both patients and medical professionals.
According to the company, Picoling is suitable for patients ranging from children aged two and older to adults. The sensor, smaller than a coin, allows for 15 days of continuous, bloodless glucose monitoring. It also features IP68-rated dust and water resistance.
Measurement data can be shared and managed by medical staff, patients, and caregivers via the dedicated smartphone app, MyPicoling. The device provides real-time tracking of glucose fluctuations, offering insights that are difficult to capture with traditional self-monitoring blood glucose (SMBG) devices or HbA1c tests.
Medical institutions can access detailed glucose data through a dedicated patient monitoring web dashboard, which also provides AI-based analytical reports.
An official from HLB Life Science stated, "Through this close partnership with Chong Kun Dang, we will strive to contribute to the widespread adoption of continuous glucose monitors and improve the quality of life for diabetic patients."
A representative from Chong Kun Dang noted that the domestic CGM market is growing at an average annual rate of over 40%, and this agreement allows the company to expand its footprint in the diabetes sector. They added, "By leveraging our diabetes treatment portfolio and sales network, we will strengthen Picoling's market competitiveness and provide more effective blood glucose management solutions to patients and medical staff."
